

VIF World 2024 Agenda

Day 1 Mar. 21

Morning Plenary Session (Diamond Hall A&B, Ground F)

Chair: Shan Lu, Professor, University of Massachusetts Medical School, US; Professor, University of Massachusetts Medical School, USA; Emeritus President, International Society for Vaccines (ISV)

0855 Opening remark

Bin Wang, Professor, Fudan University; CSO, Advaccine

0900 Plenary Panel: Next-generation vaccine technologies: innovations and challenges

Moderator: Shan Lu, Professor, University of Massachusetts Medical School, USA;
Emeritus President, International Society for Vaccines (ISV)

George Siber, President, Siber Biotechnologies LLC

Michel De Wilde, Former SVP, R&D, Sanofi Pasteur; Owner, MDW Consultant

Tao Zhu, CSO, Cansino Biologics

0945 Plenary Panel: Equitable access to vaccines: overcoming barriers and bridging Gaps

Moderator: Petro Terblanche, CEO, Afrigen Biologics, South Africa

Jian Dong, CEO, Wuxi Vaccines

Raman Rao, CEO, Hilleman Laboratories

Meng Li, Director of International Cooperation, Sinopharm CNBG

1030 Tea Break

1100 Keynote: The transformation of vaccinology: recent achievements and future prospects

Michel De Wilde, Former SVP, R&D, Sanofi Pasteur; Owner, MDW Consultant

1130 Keynote: Advancing global health through vaccines

Simon Draper, Professor, Oxford University

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

1200 Lunch (3F)

Afternoon Session

Stream A COVID & Respiratory Diamond Hall B	Stream B Bioprocessing & Manufacturing Diamond Hall A	Stream C Cancer Vaccine & Immunotherapy & RNA Diamond Hall D
<p>Chair: Tao Zhu, CSO, Cansino Biologics</p> <p>1330 Inhalable SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization Guanghai Ma, Professor/Academician, Institute of Process Engineering, CAS</p> <p>1355 Clinical development of ARCT-154, the first approved sa-mRNA vaccine Igor Smolenov Chief Development Officer, Vaccines, Arcturus Therapeutics</p> <p>1425 Africa's new public health order: lessons from covid-19 pandemic Nicaise Ndembu, Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia</p> <p>1450 Key points and considerations for non-clinical evaluation of inhaled vaccines Haifei Zhang, Senior Director, Inhalation & International Toxicology, Joynn Laboratories</p> <p>1520 Building the Respiratory Disease Vaccine Pipeline</p>	<p>Chair: Petro Terblanche, CEO, Afrigen Biologics, South Africa</p> <p>1330 Hexavalent rotavirus vaccine development Gelin Xu, Senior Expert, Wuhan Institute of Biological Products</p> <p>1355 Intranasal immunization: device and formulation promises and challenges Nektaria Karavas, Global BD Director, Aptar Pharma Julie D. Suman, Vice President of Scientific Affairs, Aptar Pharma</p> <p>1425 The development of mRNA 2.0 vaccines in HealiRNA Biotechnology Zhong Chen, VP, HealiRNA Biotech</p> <p>1450 Innovations in end-to-end mRNA vaccine research, development and manufacturing: Progress and Partnerships of the mRNA Technology Development and Transfer programme Petro Terblanche, CEO, Afrigen Biologics, South Africa</p>	<p>Chair: Kiat Ruxrungtham, Director of Chula VRC, Chulalongkorn University, Thailand</p> <p>1330 mRNA vaccines against Clostridium difficile Mohamad-Gabriel Alameh, Assistant Professor, University of Pennsylvania</p> <p>1400 mRNA Vaccine: Pandemics and Beyond - for Vaccine Equity Kiat Ruxrungtham, Director of Chula VRC, Chulalongkorn University, Thailand</p> <p>1425 Therapeutic DAN vaccine and immunotherapy (TBD) David Weiner, Executive VP, The Wistar Institute</p> <p>1450 Novel prime-boost strategy with mRNA and intratumoral oncolytic virus therapy for advanced cervical cancer Kuan Zhang, Senior Scientist, Virogin BioTech (Shanghai)</p> <p>1510 SynNeogen® immunotherapy platform— New strategies for clinical development of therapeutic vaccines for chronic hepatitis B and prostate cancer</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

<p>based on the Trimer-Tag Platform Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical</p>	<p>1515 Addressing viral manufacturing scalability challenges through fixed-bed bioreactors Rimenys Carvalho, Bioprocess Services Manager, Univercells Technologies</p>	<p>Eric Yuenian Shi, CEO, Chimigen</p>
<p>1545 Break</p> <p>1600 A bivalent RSV mRNA vaccine developed based on Innorna's mRNA/LNP technology platform Zhangjing (Jim) Chen, VP, Innorna, China</p> <p>1625 Research on in vitro titer methodology of human vaccine Le Sun, CSO, Abmax Biotechnology</p> <p>1640 Using non-changeable against changeable strategy to develop pan-HCoV vaccines Xinling Wang, Associate Professor, Fudan University, China</p> <p>1705 Intradermal DNA vaccine delivery using dissolvable microneedle patch Xiaoming Gao, VP, Advaccine, China</p> <p>1730 Inhaled vaccine, new platforms for respiratory infectious diseases Tao Zhu, CSO, Cansino Biologics</p> <p>1800 End of Day One</p>	<p>1530 Break</p> <p>1600 RNA & MAP Combining breakthrough Innovations - Towards better preparedness for the next pandemic Anna Schlüter, Head of Formulation and Process Development Microarray Patches, LTS</p> <p>1630 Regulatory considerations for Microneedle Array Patches (MAPs), as a potential new delivery system for vaccines. Maria Dul, Research Associate, Cardiff University</p> <p>1700 Ntensify™ technology a novel platform for mRNA vaccine development: case of rabies vaccine Héla KALLEL, Co-Development Products lead, Quantoom Bioscience</p> <p>1715 Tackling thermostability and biodegradation challenges in mRNA vaccine through rapid onsite microfluidic assembly (ROMA) technology Jiang Xu, Senior Scientist, Virogin Biotech</p> <p>1730 Innovating and digitalising mRNA vaccine and therapeutics production platform processes Zoltan Kis, Lecturer, University of Sheffield, UK</p> <p>1800 End of Day One</p>	<p>1530 Break</p> <p>1600 Vaccine science and design for future pandemic 100 days mission Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan</p> <p>1625 Clinical trial of an immunotherapy for the treatment of COVID-19 Mingi Chang, R&D Director, Advagene, China</p> <p>1645 End of Day One</p> <p>18:30 Welcome Reception (Invited Only)</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

Day 2 Mar. 22

Morning Session

Stream D Novel Vaccine Development Diamond Hall B

Chair: George Siber, President, Siber Biotechnologies LLC, USA

0900 Next generation pneumococcal vaccines

George Siber, President, Siber Biotechnologies

0950 Wuxi Vaccines: Empowering innovative vaccine R&D and sustainable production

Yao Pan, MSAT lead, Wuxi Vaccines

1020 New Strategies for Vaccine Immunization Evaluation System—ReadVac scRNA-seq Service Technology Platform for Vaccine Evaluation

Chongyang Liang, Professor, Jilin University;
Senior Advisor, ProMab Forethought;
Scientific Advisor, Changchun BCTH

Stream E Vaccine Design & Innovation Diamond Hall A

Chair: Linqi Zhang, Professor, Tsinghua University

0900 Harnessing germline immune memory for enhancing vaccine efficacy: new molecular mechanisms controlling memory establishment and persistence

Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology

0930 Repeated exposure to SARS-CoV-2 antigens induces exceptionally broad and potent neutralizing immunity to major sarbecoviruses in humans including SARS-CoV-1

Linqi Zhang, Professor, Tsinghua University

0955 Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody

Shaowei Li, Professor, Xiamen University

1020 Novel vaccine development: the case of bacterial infections

Aldo Tagliabue, Chief Scientist, Shenzhen Institute of Advanced Technology

Stream F Novel Platform & Partnership Diamond Hall D

Chair: Xia Jin, CEO, Co-founder, Immuno Cure BioTech

0900 Structure-Based Immunogen Design for Effective mRNA Vaccines

Baoshan Zhang, Staff Scientist, Vaccine Research Center, NIAID

0925 mRNA Nano-vaccines against EBV-positive Tumors

Xingchen Peng, Professor, West China Hospital, Sichuan University

0950 Nano-drug assembly and control technologies

Heinrich Haas, Senior Scientist, Johannes Gutenberg-Universität, Mainz

1015 AstriVax, a novel vaccine platform committed to address real world vaccinology challenges

Hanne Callewaert, CEO, AstriVax

1030 Assessment of LNP Quality & Encapsulation Efficiency by Nano-Flow Cytometry

Huijie Zhu, Application Engineer, NanoFCM

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

1040 Tea Break	1045 Tea break	1045 Tea Break
<p>1100 The thermophilic filamentous fungus, C1 - an extraordinary platform for the production of prophylactics for humans and animals Ronen Tchelet, Chief Scientific Officer, Dyadic</p> <p>1115 Pharmaceutical Research of immunoprophylaxis for antimicrobial resistant superbug Quanming Zou, Professor, Army Medical University</p> <p>1140 Helicobacter pylori vaccine development Fan Fan, VP, Head of Research Institute, Olymvax</p> <p>1205 Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases Jeff Zhu, Founder&CEO, Reinovax Biologics</p>	<p>1100 Strengthening Innovation in Vaccine R&D for Global Health Access Raman Rao, CEO, Hilleman Laboratories</p> <p>1115 Genetically engineered innovative bacterial vaccines Rong Xu, CSO, Delonix Bioworks</p> <p>1140 Broad spectrum influenza vaccine : challenges and progresses Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC</p> <p>1205 B-cell responses in vaccinated people versus infected ones Fan Yang, Professor, Shenzhen Institute of Advanced Technology</p>	<p>1100 Virogin's mRNA vaccines: from infectious disease to Cancer William Jia, CSO, Virogin/CNBG-Virogin</p> <p>1125 Assays for respiratory vaccines evaluation Emanuele Montomoli, CSO, VisMederi</p> <p>1140 Research and development of a novel human DNA vaccine platform Xia Jin, CEO, Co-founder, Immuno Cure BioTech</p> <p>1205 Developing a thermal stable mRNA RSV vaccine and beyond Yuanqing Liu, CSO, Immorna China</p>
1230 Lunch (3F)	1230 Lunch (3F)	1230 Lunch (3F)

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

Afternoon Session

Stream G Novel Vaccine Development Diamond Hall B

Chair: Shan Lu, Professor, University of Massachusetts Medical School, USA; Emeritus President, International Society for Vaccines (ISV)

1330 HIV Vaccine: Update, Immune CoP and Impact

Shan Lu, Professor, University of Massachusetts Medical School, USA; Emeritus President, International Society for Vaccines (ISV)

1400 An update of vaccine development on Hepatitis E

James Wai Kuo Shih, Senior Advisor, Xiamen Innovax Biotech, China

1425 Investigation of virus-like structure vaccine based on technological strategy of lipid delivery

Qihan Li, PI, Professor, Weirui Bio

1450 Combination vaccine development

Kutub Mahmood, Scientific Director, PATH

1515 Development of in vitro - assembled multivalent VLP vaccine for norovirus infection

Deog-Young Choi, CEO, InThera, South Korea

Stream H Adjuvant & Mucosal & Delivery Diamond Hall A

Chair: Dexiang Chen, President and CEO, Maxvax

1330 QS-21 for Advanced Adjuvants and its impact on modern vaccines

Damian Hiley, Product Manager, Desert King International
Hao Wang, CEO vuRoyal Pharmaceutical

1400 Evolution of flagellin adjuvant towards clinical application

Joon Haeng Rhee, Professor, Chonnam National University Medical School

1425 Interferons and inflammasomes in adjuvant induced immune responses

Ed Lavelle, Professor, Trinity College Dublin, Ireland

1450 Mucosal adjuvants

Elizabeth Norton, Associate Professor, Tulane University

1515 Advances in adjuvants, protein expression, and delivery technologies continue to give protein vaccines the edge; Advax-CpG adjuvant

Nikolai Petrovsky, Founder, Vaxine, Australia

Stream I Clinical Trial, Market Access Diamond Hall D

Chair: Andrew Wong, GM, Shanghai Wotai Biotechnology, Director of BD, Walvax Biotechnology

1330 Development of a monovalent XBB.1.5 mRNA Vaccine in China

Andrew Wong, GM, Shanghai Wotai Biotechnology, Director of BD, Walvax Biotechnology

1400 Vaccine Clinical Trial Strategy in SEA Market

John Mo, General Manager, Shanghai SDM

1420 Overseas vaccine registration process and declaration information requirements

Yan Liu, CEO, Medleader Bio-Pharm

1440 Evaluation on mucosal respiratory COVID -19 vaccines in clinical trials

Jingxin Li, Vice Director of the Department, Jiangsu CDC

1510 Randomized double blind Clinical Trial on Covid-19 vaccine

Muhammad Raza Shah, Professor and Director, International Center for Chemical and Biological Sciences, University of Karachi

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

1535 Tea Break	1540 Tea Break	1535 Tea Break
<p>1555 mRNA vaccine development (TBD) Yong Hu, Chairman & GM, Rhegen Bio</p> <p>1615 Progress toward AIDS vaccines Feng Gao, Professor, Ji'nan University</p> <p>1640 Development of Nanoparticle Human Vaccines Utilizing A Proprietary IC-BEVS Platform Enqi Du, GM& CSO, Chengdu Microgen</p> <p>1705 Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice Ke Xu, Professor, Wuhan University</p> <p>1730 End of Day Two</p>	<p>1555 Intranasal vaccination can build effective mucosal immunity wall against Omicron infection Ling Chen, PI, Guangzhou Laboratory</p> <p>1620 TLR5 pathway-based mucosal adjuvant for design of subunit mucosal vaccines Huimin Yan, Professor, Shanghai Public Health Clinical Center, Fudan University</p> <p>1645 Engineered design of mucus penetration nanoparticles for inhalable vaccines Bingbing Sun, Professor, Dalian University of Technology</p> <p>1700 Innovative and High-Performing Lipids for mRNA Delivery Yongming Chen, Professor, Sun Yat-sen University</p> <p>1715 Synthetic lipopeptides as vaccine adjuvants Haibo Li, Professor, Army Medical University</p> <p>1730 Panel discussion: Adjuvant technology: challenges and opportunities Moderator: Dexiang Chen, President and CEO, Maxvax</p> <p>1800 End of Day Two</p>	<p>1600 Brief introduction on Russian market regulatory procedures Arina Privalova, Strategy and Business Development, Nanolek</p> <p>1620 Driving R&D towards global public health and health equity for Vaccine: RIGHT foundation's approach Hoon Sang Lee, Chief Strategy Officer, RIGHT Foundation</p> <p>1635 End of Day Two</p>

Contact us through sam.li@chstone-events.com or 86-13482341046

VIF World 2024 Agenda

Day 3 Mar. 23

Morning Session

**Stream J Veterinary Vaccine
Diamond Hall B**

Chair: Frank Chang, CSO, Reber Genetics

0900 Developing a 'One Health' Nipah virus vaccine to protect animal and public health

Simon Graham, Professor, The Pirbright Institute, UK

0930 The Importance of specific antibodies in the development of VLP based vaccines

Huichen Guo, Professor, Lanzhou Veterinary Research Institute

1000 Targeting Chimeric Subunit Vaccines against Porcine Respiratory Pathogens

Frank Chang, CSO, Reber Genetics

1030 Tea Break

1100 mRNA based vaccine development for animal diseases

Caiyi Fei, Co-founder & VP, Therarna

1130 Next-Generation High-Yield Baculovirus/Insect Cell Protein Expression System—qBac® Bacmid

Xiaodong Xu, Professor, Northwest A&F University

1200 End of Day Three

Contact us through sam.li@chstone-events.com or 86-13482341046